Zhang Y - Search Results

1

Proposal on incorporating lymphovascular invasion as a T-descriptor for stage I lung cancer.

Wang S, Zhang B, Qian J, Qiao R, Xu J, Zhang L, Zhao Y, Zhang Y, Wang R, Zhao R, Han B. Wang S, et al. Among authors: zhang l, zhang b, zhang y. Lung Cancer. 2018 Nov;125:245-252. doi: 10.1016/j.lungcan.2018.09.024. Epub 2018 Oct 1. Lung Cancer. 2018. PMID: 30429028

2

IGF-1R and Bmi-1 expressions in lung adenocarcinoma and their clinicopathologic and prognostic significance.

Zhang X, Sun J, Wang H, Lou Y, Zhang Y, Sha H, Feng J, Han B. Zhang X, et al. Among authors: zhang y. Tumour Biol. 2014 Jan;35(1):739-45. doi: 10.1007/s13277-013-1100-9. Epub 2013 Aug 29. Tumour Biol. 2014. PMID: 23990442

3

Monitoring of carcinoembryonic antigen levels is predictive of EGFR mutations and efficacy of EGFR-TKI in patients with lung adenocarcinoma.

Zhang Y, Jin B, Shao M, Dong Y, Lou Y, Huang A, Han B. Zhang Y, et al. Tumour Biol. 2014 May;35(5):4921-8. doi: 10.1007/s13277-014-1646-1. Epub 2014 Jan 24. Tumour Biol. 2014. PMID: 24459065

4

XPA gene rs1800975 single nucleotide polymorphism and lung cancer risk: a meta-analysis.

Lou Y, Li R, Zhang Y, Zhong R, Pei J, Xiong L, Zhang X, Han B. Lou Y, et al. Among authors: zhang x, zhang y. Tumour Biol. 2014 Jul;35(7):6607-17. doi: 10.1007/s13277-014-1824-1. Epub 2014 Apr 3. Tumour Biol. 2014. PMID: 24696258

5

Notch 3 protein, not its gene polymorphism, is associated with the chemotherapy response and prognosis of advanced NSCLC patients.

Shi C, Qian J, Ma M, Zhang Y, Han B. Shi C, et al. Among authors: zhang y. Cell Physiol Biochem. 2014;34(3):743-52. doi: 10.1159/000363039. Epub 2014 Aug 19. Cell Physiol Biochem. 2014. PMID: 25171754 Free article.

6

[Value of carcinoembryonic antigen levels in predicting the efficacy of EGFR-TKI in advanced non-small cell lung cancer harboring EGFR mutations].

Jin B, Zhang Y, Zhang X, Li R, Lou Y, Niu Y, Huang A, Han B. Jin B, et al. Among authors: zhang x, zhang y. Zhonghua Yi Xue Za Zhi. 2014 Aug 13;94(30):2327-31. Zhonghua Yi Xue Za Zhi. 2014. PMID: 25399971 Chinese.

7

Mitofusin-2 over-expresses and leads to dysregulation of cell cycle and cell invasion in lung adenocarcinoma.

Lou Y, Li R, Liu J, Zhang Y, Zhang X, Jin B, Liu Y, Wang Z, Zhong H, Wen S, Han B. Lou Y, et al. Among authors: zhang x, zhang y. Med Oncol. 2015 Apr;32(4):132. doi: 10.1007/s12032-015-0515-0. Epub 2015 Mar 22. Med Oncol. 2015. PMID: 25796500

8

Transcriptional profiling revealed the anti-proliferative effect of MFN2 deficiency and identified risk factors in lung adenocarcinoma.

Lou Y, Zhang Y, Li R, Gu P, Xiong L, Zhong H, Zhang W, Han B. Lou Y, et al. Among authors: zhang w, zhang y. Tumour Biol. 2016 Jul;37(7):8643-55. doi: 10.1007/s13277-015-4702-6. Epub 2016 Jan 6. Tumour Biol. 2016. PMID: 26733181

9

Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma lung cancer patients harboring EGFR-sensitizing mutations in China.

Xu J, Zhang Y, Jin B, Chu T, Dong X, Yang H, Wu D, Lou Y, Zhang X, Wang H, Han B. Xu J, et al. Among authors: zhang x, zhang y. J Cancer Res Clin Oncol. 2016 Jun;142(6):1325-30. doi: 10.1007/s00432-016-2133-4. Epub 2016 Mar 4. J Cancer Res Clin Oncol. 2016. PMID: 26942444

10

EGFR tyrosine kinase inhibitor (TKI) in patients with advanced non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: A real-world study in China.

Xu J, Jin B, Chu T, Dong X, Yang H, Zhang Y, Wu D, Lou Y, Zhang X, Wang H, Han B. Xu J, et al. Among authors: zhang x, zhang y. Lung Cancer. 2016 Jun;96:87-92. doi: 10.1016/j.lungcan.2016.01.018. Epub 2016 Jan 30. Lung Cancer. 2016. PMID: 27133756

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

261,435 results

Search Page

Filters